MALVERN, Pa. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced
MALVERN, Penn. — October 10, 2019 — Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced Christopher Degnan has been
Data reinforce potential of GC4419 to become a promising treatment for reducing the incidence of severe oral mucositis in patients with head and neck cancer MALVERN, Penn. — October 8, 2019 — Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and
Data to be published in the Journal of the National Comprehensive Cancer Network MALVERN, Penn. — March 21, 2019 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer
MALVERN, Penn. — October 23, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data from its Phase 2b clinical trial evaluating avasopasem
Data from pivotal trial of avasopasem manganese for the reduction of severe oral mucositis in patients with head and neck cancer intended to support New Drug Application MALVERN, Penn. — October 15, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development
Pivotal trial of GC4419 for the treatment of severe oral mucositis in patients with head and neck cancer expected to initiate in fourth quarter 2018 MALVERN, Penn. — September 19, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting
Presentation selected as part of The Halpern Legacy Symposium and press program Phase 3 trial of GC4419 for treatment of severe oral mucositis in patients with head and neck cancer expected to initiate in fourth quarter 2018 MALVERN, Penn. — Aug. 20, 2018 — Galera Therapeutics, Inc., a
GC4419 demonstrated clinically significant reduction in duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer Trial investigator Dr. Carryn Anderson honored with Steven M. Grunberg Memorial Award for excellence in cancer research MALVERN, Penn.
Abstract receives Steven M. Grunberg Memorial Award for excellence in cancer research MALVERN, Penn. — June 12, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer
